Agger EM - Search Results

1

An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines.

Jong WS, Daleke-Schermerhorn MH, Vikström D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, van de Sandt CE, Rimmelzwaan GF, Follmann F, Agger EM, Andersen P, de Gier JW, Luirink J. Jong WS, et al. Among authors: agger em. Microb Cell Fact. 2014 Nov 25;13:162. doi: 10.1186/s12934-014-0162-8. Microb Cell Fact. 2014. PMID: 25421093 Free PMC article.

2

Tuberculosis subunit vaccine development: on the role of interferon-gamma.

Agger EM, Andersen P. Agger EM, et al. Vaccine. 2001 Mar 21;19(17-19):2298-302. doi: 10.1016/s0264-410x(00)00519-3. Vaccine. 2001. PMID: 11257351

3

A novel TB vaccine; towards a strategy based on our understanding of BCG failure.

Agger EM, Andersen P. Agger EM, et al. Vaccine. 2002 Nov 22;21(1-2):7-14. doi: 10.1016/s0264-410x(02)00447-4. Vaccine. 2002. PMID: 12443657 Review.

4

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.

Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, Werninghaus K, Kirschning C, Lang R, Christensen D, Theisen M, Follmann F, Andersen P. Agger EM, et al. PLoS One. 2008 Sep 8;3(9):e3116. doi: 10.1371/journal.pone.0003116. PLoS One. 2008. PMID: 18776936 Free PMC article.

5

PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family.

Okkels LM, Brock I, Follmann F, Agger EM, Arend SM, Ottenhoff TH, Oftung F, Rosenkrands I, Andersen P. Okkels LM, et al. Among authors: agger em. Infect Immun. 2003 Nov;71(11):6116-23. doi: 10.1128/IAI.71.11.6116-6123.2003. Infect Immun. 2003. PMID: 14573626 Free PMC article.

6

Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.

Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. Hansen J, et al. Among authors: agger em. J Infect Dis. 2008 Sep 1;198(5):758-67. doi: 10.1086/590670. J Infect Dis. 2008. PMID: 18652549

7

High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Lindenstrøm T, Aagaard C, Christensen D, Agger EM, Andersen P. Lindenstrøm T, et al. Among authors: agger em. Eur J Immunol. 2014 Jun;44(6):1699-709. doi: 10.1002/eji.201344358. Epub 2014 Mar 27. Eur J Immunol. 2014. PMID: 24677089 Free PMC article.

8

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells.

Lindenstrøm T, Knudsen NP, Agger EM, Andersen P. Lindenstrøm T, et al. Among authors: agger em. J Immunol. 2013 Jun 15;190(12):6311-9. doi: 10.4049/jimmunol.1300248. Epub 2013 May 15. J Immunol. 2013. PMID: 23677471

9

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P. Andersen CS, et al. Among authors: agger em. Infect Immun. 2007 Jan;75(1):408-16. doi: 10.1128/IAI.01290-06. Epub 2006 Oct 30. Infect Immun. 2007. PMID: 17074845 Free PMC article.

10

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.

Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. Lindenstrøm T, et al. Among authors: agger em. J Immunol. 2009 Jun 15;182(12):8047-55. doi: 10.4049/jimmunol.0801592. J Immunol. 2009. PMID: 19494330

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page